| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Over the last 12 months, insiders at Indaptus Therapeutics, Inc. have bought $0 and sold $0 worth of Indaptus Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Indaptus Therapeutics, Inc. have bought $163,428 and sold $100,043 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 23,934 shares for transaction amount of $56,006 was made by Anderson Glen R. (10 percent owner) on 2023‑08‑14.
| 2023-08-14 | Anderson Glen R. | 10 percent owner | 23,934 0.2688% | $2.34 | $56,006 | -11.29% | ||
| 2023-08-11 | Anderson Glen R. | 10 percent owner | 35,064 0.3798% | $2.12 | $74,336 | -4.35% | ||
| 2023-08-10 | Anderson Glen R. | 10 percent owner | 44,354 0.482% | $1.94 | $86,047 | -0.45% | ||
| 2022-12-01 | Litchev Boyan Vesselinov | Chief Medical Officer | 500 0.0063% | $1.87 | $935 | +8.94% | ||
| 2022-11-22 | Litchev Boyan Vesselinov | Chief Medical Officer | 500 0.0061% | $1.83 | $915 | +4.95% | ||
| 2022-11-21 | Meckler Jeffrey A | CEO and Director | 9,600 0.122% | $1.90 | $18,240 | +4.97% | ||
| 2022-11-18 | Meckler Jeffrey A | CEO and Director | 400 0.0047% | $1.76 | $705 | +4.97% | ||
| 2022-09-08 | Meckler Jeffrey A | CEO and Director | 10,308 0.1329% | $2.80 | $28,862 | -29.66% | ||
| 2022-09-07 | Linscott Walt Addison | Chief Business Officer | 150 0.0018% | $2.62 | $393 | -29.39% | ||
| 2022-09-06 | Meckler Jeffrey A | CEO and Director | 8,632 0.1092% | $2.57 | $22,184 | -24.80% | ||
| 2022-06-06 | Meckler Jeffrey A | CEO and Director | 19,727 0.2371% | $2.63 | $51,882 | -28.68% | ||
| 2022-03-02 | Litchev Boyan Vesselinov | Chief Medical Officer | 50 0.0006% | $4.09 | $205 | -42.65% | ||
| 2022-02-01 | Sale | Newman Michael James | CSO and Director | 14,130 0.1722% | $5.00 | $70,692 | -49.70% | |
| 2022-01-31 | Sale | Newman Michael James | CSO and Director | 5,870 0.0712% | $5.00 | $29,351 | -49.90% | |
| 2022-01-31 | Litchev Boyan Vesselinov | Chief Medical Officer | 100 0.0011% | $4.65 | $465 | -49.90% | ||
| 2021-11-18 | Meckler Jeffrey A | CEO and Director | 11,187 0.2847% | $5.82 | $65,108 | -44.81% | ||
| 2021-09-14 | Meckler Jeffrey A | CEO and Director | 12,000 0.2842% | $7.00 | $84,000 | -43.28% |
| Newman Michael James | CSO and Director | 1368356 78.1463% | $3.57M | 0 | 2 | |
| Anderson Glen R. | 10 percent owner | 1190400 67.9833% | $3.11M | 3 | 0 | |
| Meckler Jeffrey A | CEO and Director | 75374 4.3046% | $196,726.14 | 7 | 0 | <0.0001% |
| Litchev Boyan Vesselinov | Chief Medical Officer | 1150 0.0657% | $3,001.50 | 4 | 0 | <0.0001% |
| Linscott Walt Addison | Chief Business Officer | 150 0.0086% | $391.50 | 1 | 0 |
$22,360,243 | 40 | 22.92% | $4.13M | |
$1,029,337 | 36 | -28.38% | $6.62M | |
$1,138,733 | 28 | -4.94% | $4.73M | |
$29,635,355 | 27 | 9.05% | $6.29M | |
$547,862 | 19 | -29.82% | $4.88M | |
$8,079,884 | 14 | -43.20% | $4.29M | |
$105,917 | 11 | -28.06% | $3.63M | |
$20,715,938 | 10 | -42.51% | $6.23M | |
$90,087 | 9 | 20.06% | $6.54M | |
$16,172 | 9 | -21.60% | $3.62M | |
$8,971,546 | 8 | 6.18% | $5.64M | |
$70,828 | 6 | -57.96% | $2.37M | |
$59,059 | 6 | -60.20% | $3.15M | |
$726,438 | 4 | -72.85% | $3.75M | |
Indaptus Therapeutics, Inc. (INDP) | $149,778 | 4 | -45.16% | $4.57M |
$4,423 | 2 | 3.27% | $5.73M | |
$739,010 | 1 | 3.33% | $4.06M | |
$37,000 | 1 | 79.42% | $4.04M | |
$19,863 | 1 | 144.27% | $4.65M |
| Increased Positions | 4 | +50% | 19,866 | +1,057.83% |
| Decreased Positions | 4 | -50% | 154 | -8.2% |
| New Positions | 2 | New | 19,499 | New |
| Sold Out Positions | 2 | Sold Out | 12 | Sold Out |
| Total Postitions | 8 | 0% | 21,590 | +1,049.63% |
| Virtu Financial Llc | $47.00 | 0.95% | 18,997 | +18,997 | New | 2025-09-30 |
| Pine Valley Investments Ltd Liability Co | $4.00 | 0.08% | 1,568 | -3 | -0.19% | 2024-12-31 |
| Ubs Group Ag | $1.00 | 0.03% | 502 | +502 | New | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $1.00 | 0.02% | 473 | +365 | +337.96% | 2025-09-30 |
| Bank Of America Corp /De/ | $0 | <0.01% | 33 | +2 | +6.45% | 2025-09-30 |
| Sbi Securities Co., Ltd. | $0 | <0.01% | 17 | -139 | -89.1% | 2025-09-30 |
| Fmr Llc | $0 | 0% | 0 | -10 | Sold Out | 2025-09-30 |
| Wells Fargo & Company/Mn | $0 | 0% | 0 | -2 | Sold Out | 2025-09-30 |